Patient: Feminine, 68-year-old Last Diagnosis: Chordoma Symptoms: Hoarseness ? throat pain ? weakness Medication: Clinical Method: Area of expertise: Oncology Objective: Unforeseen or Uncommon aftereffect of treatment Background: Chordoma is rare, but aggressive bone tissue tumor, impacting the axial skeleton primarily. afatinib with great impact. Conclusions: This post discusses the potency of afatanib as cure… Continue reading Patient: Feminine, 68-year-old Last Diagnosis: Chordoma Symptoms: Hoarseness ? throat pain ? weakness Medication: Clinical Method: Area of expertise: Oncology Objective: Unforeseen or Uncommon aftereffect of treatment Background: Chordoma is rare, but aggressive bone tissue tumor, impacting the axial skeleton primarily
Category: Histone Methyltransferases
Trastuzumab-resistance is still a major challenge in treating patients with HER2 positive breast cancer
Trastuzumab-resistance is still a major challenge in treating patients with HER2 positive breast cancer. and BT474 cells. Addition of anti-PD1 antibody further enhanced the cytotoxicity of anti-HER2 CAR-T cells against HCC1954 cells. Lastly, shot of anti-HER2 CAR-T cells reduced the development of HCC1954 xenograft tumors significantly. Merging anti-HER2 CAR-T cells with anti-PD1 antibody impaired the… Continue reading Trastuzumab-resistance is still a major challenge in treating patients with HER2 positive breast cancer